Loading…
Insmed Inc Is A Biopharmaceutical Company. Its Commercial Portfolio And Clinical Pipeline Are Organized Around Three Therapeutic Areas: Respiratory, Immunology And Inflammation, And Neuro And Other Rare. The Company'S Two Commercial Products, Arikayce And Brinsupri, Are Both Part Of The Respiratory Therapeutic Area. The Firm'S Clinical-Stage Programs Are Tpip, Ins1148, Brensocatib, And Ins1201, Focusing On Different Therapeutic Areas. Additionally, Insmed'S Pre-Clinical Research Programs Encompass Various Technologies And Modalities, Including Gene Therapy, Ai-Driven Protein Engineering, Protein Manufacturing, Rna End-Joining, And Synthetic Rescue. Geographically, The Company Generates Maximum Revenue From The United States From The Sale Of Its Commercial Products.